Sir,
Over the past several years, positron emission tomography (PET) has become an important diagnostic modality for evaluation of solid malignant lesions.1 In contrast with computerized tomography and magnetic resonance imaging, which detect structural abnormalities, PET scan relies on altered metabolism within a malignant cell to detect tissue abnormalities. Malignant cells have a higher rate of glucose uptake and therefore show preferential uptake of radiolabeled Fluorine-18 fluorodeoxyglucose (FDG).2 FDG undergoes spontaneous decay emitting positrons with a half life of 110 min. The anatomic localization of FDG entrapment is improved with sequential imaging of the corresponding areas using noncontrast computerized tomography (CT) and a fused image is generated for diagnostic evaluation.
We performed a pilot study on a consecutive prospective series of 10 patients who were clinically diagnosed with primary uveal melanoma. Each patient underwent whole body FDG-PET/CT scan as part of work up for metastasis prior to treatment on Siemens Biograph16 system (Hoffman Estates, IL, USA). The scan was performed after the patient had been fasting for at least four hours. FDG dose was approximately 10–12 mCi (370–444 MBq) given intravenously. The maximum standardized uptake value (SUV) was measured in cases where the primary tumour could be visualized. CT was carried out at the same setting. Correlation was attempted between tumour size and identification of the tumour by PET/CT scan.
Comment
Overall, the diagnostic accuracy of uveal melanoma is more than 99% based on indirect ophthalmoscopy, ultrasonographic, and angiographic studies.3 Therefore, the role of ancillary studies such as immunoscintigraphy,4 CT,5 and magnetic resonance imaging is used to establish the diagnosis6 is limited to the atypical cases.
In our series, uveal melanoma could be detected with FDG-PET/CT scan in six of 10 (60%) patients (Figure 1). Each tumour appeared to demonstrate relatively uniform uptake and the intensity of FDG uptake (as measured by maximum SUV) varied between tumours from 3.5 to 8.6. Tumours that were at least 13 mm in diameter, 4.5 mm in height, 125 mm2 in scleral contact area, or 565 mm3 volume were visualized (Table 1).
PET evaluation of smaller lesions is limited.7, 8 It is conceivable that additional factors affecting tumour glucose metabolism such as tumour necrosis, intratumoural haemorrhage, and inflammation could influence tumour visualization.8 As PET/CT scan is a test of metabolic activity of the tissues, it may have a potential in evaluating tumour response following plaque radiotherapy especially in cases with questionable clinical response.9
References
Jerusalem G, Hustinx R, Beguin Y, Fillet G . PET scan imaging in oncology. Eur J Cancer 2003; 39: 1525–1534.
Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP . Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19: 1154–1161.
COMS Group. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS report no. 1. Arch Ophthalmol 1990; 108: 1268–1273.
Bomanji J, Hungerford JL, Granowska M, Britton KE . Radioimmunoscintigraphy of ocular melanoma with 99mTc labelled cutaneous melanoma antibody fragments. Br J Ophthalmol 1987; 71: 651–658.
Augsburger JJ, Peyster RG, Markoe AM, Guillet EG, Shields JA, Haskin ME . Computed tomography of posterior uveal melanomas. Arch Ophthalmol 1987; 105: 1512–1516.
De Potter P, Flanders AE, Shields JA, Shields CL, Gonzales CF, Rao VM . The role of fat-suppression technique and gadopentetate dimeglumine in magnetic resonance imaging evaluation of intraocular tumors and simulating lesions. Arch Ophthalmol 1994; 112: 340–348.
Spraul CW, Lang GE, Lang GK . Value of positron emission tomography in the diagnosis of malignant ocular tumors. Ophthalmologica 2001; 215: 163–168.
Modorati G, Lucignani G, Landoni C, Freschi M, Trabucchi G, Fazio F et al. Glucose metabolism and pathological findings in uveal melanoma: preliminary results. Nucl Med Commun 1996; 17: 1052–1056.
Pe’er J, Stefani FH, Seregard S, Kivela T, Lommatzsch P, Prause JU et al. Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study. Br J Ophthalmol 2001; 85: 1208–1212.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Singh, A., Bhatnagar, P. & Bybel, B. Visualization of primary uveal melanoma with PET/CT scan. Eye 20, 938–940 (2006). https://doi.org/10.1038/sj.eye.6702044
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.eye.6702044
This article is cited by
-
Choroidal biopsies; a review and optimised approach
Eye (2023)
-
A prospective analysis of 18F-FDG PET/CT in patients with uveal melanoma: comparison between metabolic rate of glucose (MRglu) and standardized uptake value (SUV) and correlations with histopathological features
European Journal of Nuclear Medicine and Molecular Imaging (2013)